← Leaderboards
Surinder Kumar Batra
University Of Pittsburgh At Pittsburgh
$34,830,369
Attributed
$54,949,637
Total exposure
28
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$67,306,361 · 30
By mechanism
R01$34,044,033 · 17
U01$14,776,411 · 3
P01$10,951,611 · 3
U54$5,490,424 · 4
P50$1,901,154 · 2
R03$142,728 · 1
Top collaborators
- Randall Brand16 shared
- Moorthy P. Ponnusamy12 shared
- Maneesh Jain10 shared
- Michael A Hollingsworth6 shared
- Anna E Lokshin5 shared
- Michel M Ouellette5 shared
- Ravi Salgia5 shared
- Rakesh K Singh5 shared
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
- Monica M Bertagnolli · Strang Cancer Prevention Center$20,383,871
Research focus
Malignant Neoplasm Of PancreasMalignant NeoplasmsTumorNeoplasm MetastasisIn VivoCellsTumor ProgressionMouse ModelPancreasBaseTissuesMucinsPancreatic NeoplasmOverexpressionDiagnosisIn VitroSamplingMolecularSignal TransductionGenesPathway InteractionsMediatingOncogenicNeoplastic Cell
Grant awards (157)
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma$1,264,325
U01 · FY2025 · CA
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer$1,028,395
R01 · FY2025 · CA
Connectivity mapping identified novel combination therapy for glioblastoma$891,835
R01 · FY2025 · CA
Artificial intelligence enabled Stroma-Weighted Automated Grading system to improve risk stratification in Black Men$717,667
R01 · FY2025 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$609,412
R01 · FY2025 · CA
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer$450,008
R01 · FY2025 · CA
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer$114,096
R01 · FY2025 · CA
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma$1,201,109
U01 · FY2024 · CA
Novel Therapy to Inhibit IPMN Progression$635,784
R01 · FY2024 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$584,995
R01 · FY2024 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$573,438
R01 · FY2024 · CA
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer$488,488
R01 · FY2024 · CA
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer$427,508
R01 · FY2024 · CA
Connectivity mapping identified novel combination therapy for glioblastoma$423,622
R01 · FY2024 · CA
Novel Therapy to Inhibit IPMN Progression$74,401
R01 · FY2024 · CA
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer$52,806
R01 · FY2024 · CA
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma$915,566
U01 · FY2023 · CA
Novel Therapy to Inhibit IPMN Progression$655,860
R01 · FY2023 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$622,418
R01 · FY2023 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$535,359
R01 · FY2023 · CA
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer$503,508
R01 · FY2023 · CA
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer$441,011
R01 · FY2023 · CA
Connectivity mapping identified novel combination therapy for glioblastoma$436,999
R01 · FY2023 · CA
Pancreatic Cancer Metastasis$1,611,403
P01 · FY2022 · CA · contact PI
Novel Therapy to Inhibit IPMN Progression$686,204
R01 · FY2022 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$626,416
R01 · FY2022 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$535,359
R01 · FY2022 · CA
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer$526,941
R01 · FY2022 · CA
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer$464,170
R01 · FY2022 · CA
Connectivity mapping identified novel combination therapy for glioblastoma$445,918
R01 · FY2022 · CA
Targeting CXCR2 axis in Pancreatic Cancer$394,508
R01 · FY2022 · CA
Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis$308,947
P01 · FY2022 · CA · contact PI
Core 1: Administrative and Bioinformatics Core$248,087
P01 · FY2022 · CA · contact PI
Pancreatic Cancer Metastasis$1,644,289
P01 · FY2021 · CA · contact PI
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$637,390
R01 · FY2021 · CA
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$617,452
U01 · FY2021 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$567,785
R01 · FY2021 · CA
Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia$421,180
R01 · FY2021 · CA
Targeting CXCR2 axis in Pancreatic Cancer$402,559
R01 · FY2021 · CA
Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis$315,252
P01 · FY2021 · CA · contact PI
Core 1: Administrative and Bioinformatics Core$253,150
P01 · FY2021 · CA · contact PI
Pancreatic Cancer Metastasis$1,644,289
P01 · FY2020 · CA · contact PI
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$875,414
U01 · FY2020 · CA
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer$614,511
R01 · FY2020 · CA
Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia$421,180
R01 · FY2020 · CA
Targeting CXCR2 axis in Pancreatic Cancer$402,559
R01 · FY2020 · CA
Rac1 GTPase in tumorigenesis and progression of pancreatic cancer$374,745
R01 · FY2020 · CA
Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis$315,252
P01 · FY2020 · CA · contact PI
Core 1: Administrative and Bioinformatics Core$253,150
P01 · FY2020 · CA · contact PI
Pancreatic Cancer Metastasis$1,594,959
P01 · FY2019 · CA · contact PI
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$857,224
U01 · FY2019 · CA
Targeted Radiation Therapy for Pancreatic Cancer$422,866
R01 · FY2019 · CA · contact PI
Targeting CXCR2 axis in Pancreatic Cancer$390,482
R01 · FY2019 · CA
Rac1 GTPase in tumorigenesis and progression of pancreatic cancer$363,502
R01 · FY2019 · CA
Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia$362,607
R01 · FY2019 · CA
Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis$305,795
P01 · FY2019 · CA · contact PI
MIC-1 and its functional partners in prostate cancer racial disparity$302,717
U01 · FY2019 · CA · contact PI
Core 1: Administrative and Bioinformatics Core$245,555
P01 · FY2019 · CA · contact PI
Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia$47,357
R01 · FY2019 · CA
Pancreatic Cancer Metastasis$1,643,391
P01 · FY2018 · CA · contact PI
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$1,563,388
U01 · FY2018 · CA
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2018 · CA · contact PI
Targeting CXCR2 axis in Pancreatic Cancer$401,679
R01 · FY2018 · CA
Rac1 GTPase in tumorigenesis and progression of pancreatic cancer$374,745
R01 · FY2018 · CA
Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia$373,823
R01 · FY2018 · CA
Novel Target(s) in the Radiosensitization of Pancreatic Cancer$366,080
P50 · FY2018 · CA · contact PI
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2018 · GM
Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis$315,080
P01 · FY2018 · CA · contact PI
MIC-1 and its functional partners in prostate cancer racial disparity$312,080
U01 · FY2018 · CA · contact PI
Targeting Mucin and EGFR Axis in Pancreatic Cancer$311,659
R01 · FY2018 · CA · contact PI
Core 1: Administrative and Bioinformatics Core$253,012
P01 · FY2018 · CA · contact PI
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$1,537,769
U01 · FY2017 · CA
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2017 · CA · contact PI
Novel Target(s) in the Radiosensitization of Pancreatic Cancer$378,716
P50 · FY2017 · CA · contact PI
Rac1 GTPase in tumorigenesis and progression of pancreatic cancer$374,745
R01 · FY2017 · CA
Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia$373,823
R01 · FY2017 · CA
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2017 · GM
MIC-1 and its functional partners in prostate cancer racial disparity$312,080
U01 · FY2017 · CA · contact PI
Targeting Mucin and EGFR Axis in Pancreatic Cancer$311,659
R01 · FY2017 · CA · contact PI
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$129,694
U01 · FY2017 · CA
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$902,819
U01 · FY2016 · CA
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2016 · CA · contact PI
Rac1 GTPase in tumorigenesis and progression of pancreatic cancer$374,745
R01 · FY2016 · CA
Novel Target(s) in the Radiosensitization of Pancreatic Cancer$364,128
P50 · FY2016 · CA · contact PI
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2016 · GM
MIC-1 and its functional partners in prostate cancer racial disparity$312,080
U01 · FY2016 · CA · contact PI
Targeting Mucin and EGFR Axis in Pancreatic Cancer$311,659
R01 · FY2016 · CA · contact PI
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$171,812
U01 · FY2016 · CA
Pancreatic Tumor Micro-environment Network$938,351
U54 · FY2015 · CA · contact PI
Targeted Radiation Therapy for Pancreatic Cancer$435,945
R01 · FY2015 · CA · contact PI
Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer$356,087
R01 · FY2015 · GM
Novel Target(s) in the Radiosensitization of Pancreatic Cancer$325,622
P50 · FY2015 · CA · contact PI
MIC-1 and its functional partners in prostate cancer racial disparity$324,705
U01 · FY2015 · CA · contact PI
Targeting Mucin and EGFR Axis in Pancreatic Cancer$311,659
R01 · FY2015 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$197,326
U01 · FY2015 · CA
Interplay of Tumor Microenvironment and MUC4 in Pancreatic Cancer$176,545
U54 · FY2015 · CA · contact PI
Rapid Autopsy Program$63,919
U54 · FY2015 · CA · contact PI
Administrative Core$49,888
U54 · FY2015 · CA · contact PI
Pancreatic Tumor Micro-environment Network$775,167
U54 · FY2014 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$555,169
U01 · FY2014 · CA
Novel Target(s) in the Radiosensitization of Pancreatic Cancer$364,127
P50 · FY2014 · CA · contact PI
Novel deregulated genes in the etiology and progression of human prostate cancer$347,495
R01 · FY2014 · CA · contact PI
Targeting Mucin and EGFR Axis in Pancreatic Cancer$311,659
R01 · FY2014 · CA · contact PI
Interplay of Tumor Microenvironment and MUC4 in Pancreatic Cancer$173,230
U54 · FY2014 · CA · contact PI
Rapid Autopsy Program$59,956
U54 · FY2014 · CA · contact PI
Administrative Core$46,222
U54 · FY2014 · CA · contact PI
Novel deregulated genes in the etiology and progression of human prostate cancer$9,522
R01 · FY2014 · CA · contact PI
Pancreatic Tumor Micro-environment Network$854,923
U54 · FY2013 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$549,264
U01 · FY2013 · CA
Novel deregulated genes in the etiology and progression of human prostate cancer$336,747
R01 · FY2013 · CA · contact PI
Interplay of Tumor Microenvironment and MUC4 in Pancreatic Cancer$310,162
U54 · FY2013 · CA · contact PI
Targeting MUC4 for chemosensitization of pancreatic cancer$69,157
R03 · FY2013 · CA · contact PI
Rapid Autopsy Program$55,221
U54 · FY2013 · CA · contact PI
Novel deregulated genes in the etiology and progression of human prostate cancer$44,583
R01 · FY2013 · CA · contact PI
Administrative Core$43,627
U54 · FY2013 · CA · contact PI
Pancreatic Tumor Micro-environment Network$818,351
U54 · FY2012 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$594,573
U01 · FY2012 · CA
Novel deregulated genes in the etiology and progression of human prostate cancer$358,242
R01 · FY2012 · CA · contact PI
Smoking and pancreatic cancer$307,952
R01 · FY2012 · CA · contact PI
Molecular Markers for the Diagnosis of Pancreatic Cancer$297,686
R01 · FY2012 · CA · contact PI
Interplay of Tumor Microenvironment and MUC4 in Pancreatic Cancer$178,459
U54 · FY2012 · CA · contact PI
Targeting MUC4 for chemosensitization of pancreatic cancer$73,571
R03 · FY2012 · CA · contact PI
Rapid Autopsy Program$63,957
U54 · FY2012 · CA · contact PI
Administrative Core$50,845
U54 · FY2012 · CA · contact PI
Biomarker(s) for the diagnosis of pancreatic cancer$45,066
P50 · FY2012 · CA · contact PI
Novel deregulated genes in the etiology and progression of human prostate cancer$37,614
R01 · FY2012 · CA · contact PI
Pancreatic Tumor Micro-environment Network$831,601
U54 · FY2011 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$606,189
U01 · FY2011 · CA
Novel deregulated genes in the etiology and progression of human prostate cancer$358,242
R01 · FY2011 · CA · contact PI
Smoking and pancreatic cancer$307,952
R01 · FY2011 · CA · contact PI
Molecular Markers for the Diagnosis of Pancreatic Cancer$297,686
R01 · FY2011 · CA · contact PI
Molecular Studies on MUC4 Mucin Gene$217,319
R01 · FY2011 · CA · contact PI
Biomarker(s) for the diagnosis of pancreatic cancer$57,415
P50 · FY2011 · CA · contact PI
Early Diagnosis of Pancreatic Cancer$673,656
U01 · FY2010 · CA
Novel deregulated genes in the etiology and progression of human prostate cancer$369,322
R01 · FY2010 · CA · contact PI
Smoking and pancreatic cancer$317,476
R01 · FY2010 · CA · contact PI
Molecular Markers for the Diagnosis of Pancreatic Cancer$306,893
R01 · FY2010 · CA · contact PI
Molecular Studies on MUC4 Mucin Gene$224,040
R01 · FY2010 · CA · contact PI
Smoking and pancreatic cancer$52,429
R01 · FY2010 · CA · contact PI
Smoking and pancreatic cancer$317,165
R01 · FY2009 · CA · contact PI
Molecular Markers for the Diagnosis of Pancreatic Cancer$306,893
R01 · FY2009 · CA · contact PI
Molecular Studies on MUC4 Mucin Gene$224,040
R01 · FY2009 · CA · contact PI
Molecular Studies on MUC4 Mucin Gene$133,919
R01 · FY2009 · CA · contact PI
Smoking and pancreatic cancer$81,342
R01 · FY2009 · CA · contact PI
Smoking and pancreatic cancer$328,603
R01 · FY2008 · CA · contact PI
Molecular Markers for the Diagnosis of Pancreatic Cancer$318,643
R01 · FY2008 · CA · contact PI
Molecular Studies on MUC4 Mucin Gene$224,040
R01 · FY2008 · CA · contact PI
Smoking and pancreatic cancer$38,211
R01 · FY2008 · CA · contact PI
Molecular Studies on MUC4 Mucin Gene$215,318
R01 · FY2006 · CA · contact PI
Molecular Studies on MUC4 Mucin Gene$220,500
R01 · FY2005 · CA
Molecular Studies on MUC4 Mucin Gene$7,507
R01 · FY2005 · CA
Molecular Studies on MUC4 Mucin Gene$220,500
R01 · FY2004 · CA
Molecular Studies on MUC4 Mucin Gene$7,507
R01 · FY2004 · CA
Molecular Studies on MUC4 Mucin Gene$220,500
R01 · FY2003 · CA
Molecular Studies on MUC4 Mucin Gene$229,500
R01 · FY2002 · CA
MOLECULAR STUDIES ON MUC4 MUCIN GENE$194,235
R01 · FY2001 · CA
MOLECULAR STUDIES ON MUC4 MUCIN GENE$188,578
R01 · FY2000 · CA